Abstract
Background and importanceTrastuzumab-emtansine (T-DM1) is a treatment approved by the European Medicines Agency (EMA) in 2020 as a single agent for the adjuvant treatment of adult patients with HER2-positive early...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have